Another big hospital chain has landed on Dalal Street, and this one is not a small bet. Manipal Health Enterprises, the company behind the widely recognised Manipal Hospitals brand, opened its Rs. 9,275 crore IPO on 29 July and the book closes on 31 July 2026. If you have been staring at your broker app wondering whether to apply, or whether this is simply another richly priced hospital stock riding India's healthcare boom, you are not alone. Here is what the numbers actually say, and whether this one deserves a place in a long term portfolio rather than just a listing day flip.

IPO Details at a Glance

The price band is fixed at Rs. 560 to Rs. 590 per share of face value Rs. 2. The minimum lot size is 25 shares, which works out to roughly Rs. 14,750 at the upper band. Retail investors can apply for up to 13 lots, or 325 shares, taking the maximum retail application to about Rs. 1,91,750. The issue is a mix of a fresh issue and an offer for sale, adding up to a total size of around Rs. 9,275 crore. Anchor investor bidding happened on 28 July, the subscription window runs from 29 to 31 July 2026, allotment is expected on 3 August, and listing on both BSE and NSE is scheduled for 5 August. KFin Technologies is handling the registrar duties, with Kotak Mahindra Capital, Axis Capital, Goldman Sachs India and Jefferies India running the book.

On day one, overall subscription stood at a modest 0.14 times, with retail bids at around 0.23 times, which is fairly typical for a large mainboard issue since institutional money tends to show up only on the last day. If you are also tracking the other names open around the same time, we covered the subscription trends for two smaller issues in this week's IPO watch, and if you want a broader sense of how to approach any new listing this year, our guide on whether retail investors should apply to 2026 IPOs is a useful starting point.

What Manipal Health Actually Runs

Manipal Health Enterprises was incorporated in 2010 and sits under the wider Manipal Group, founded by Dr T M A Pai. The company is led by promoter Dr Ranjan Ramdas Pai, and promoter holding will come down from 81.43 percent to about 72.08 percent once the IPO shares are allotted. Headquartered in Bengaluru, the group has heavy concentration in Bengaluru, Kolkata and Pune, which together account for close to 40 percent of its total bed capacity.

By licensed bed count, Manipal is the largest private hospital network in the country at 13,037 beds, and the second largest by revenue after Apollo Hospitals. But here is the catch worth noticing: only about 6,878 beds, under 70 percent of the licensed capacity, were actually operational through FY26. A large chunk of the network still needs to be activated and filled with patients before it starts paying for itself.

A big part of the recent growth story is the Sahyadri Hospitals acquisition, a 90 percent stake in the Pune based, 1,606 bed chain picked up in the third quarter of FY26. This was funded through Rs. 5,310 crore of non convertible debentures carrying a 9 percent coupon, which has meaningfully added to the company's debt load. Separately, in March 2026, the company issued 2.38 crore shares, about 1.8 percent of its post IPO equity, to the Manipal promoter group in exchange for a perpetual licence to use the Manipal brand name. At the IPO price, that transaction is worth close to Rs. 1,400 crore, and a few analysts have flagged it as an unusually large related party deal to push through right before a listing.

The Financial Picture

Revenue for FY26 came in at Rs. 10,520 crore, up 26 percent from Rs. 8,363 crore in FY25. Profit after tax, however, actually fell around 15 percent to Rs. 917 crore from Rs. 1,082 crore a year earlier, largely because of the higher interest burden from the Sahyadri debt. Basic EPS works out to Rs. 7.71 and diluted EPS to Rs. 7.67, with a net asset value of Rs. 72.55 per share and a return on net worth of 10.57 percent.

How Manipal Stacks Up Against Listed Hospital Chains

Manipal will not be trading in isolation. Apollo Hospitals, Fortis Healthcare and Max Healthcare are the three big listed names investors will naturally compare it with, and the picture changes depending on which yardstick you use.

Manipal's occupancy, at under 65 percent, is the lowest of the four, which means it is carrying more unused bed capacity than any of its listed peers right now. But on EV to EBITDA, a measure that accounts for the debt sitting on the balance sheet, Manipal actually looks cheaper than Fortis and only a touch pricier than Max. On a plain trailing price to earnings basis though, Manipal comes in at around 85 times, noticeably above the 65 to 75 times range Apollo, Fortis and Max are currently trading at. Which number matters more to you depends on how comfortable you are with the extra debt Manipal took on for the Sahyadri deal. If you have been wondering whether the broader market itself is trading rich at the moment, our piece on whether Nifty 50 is overvalued on a PE basis walks through similar logic, and much of it applies just as well at the individual stock level.

What Brokerages Are Saying

Marwadi Financial Services has given the issue an Avoid rating, pointing directly at the valuation gap with listed peers. SP Tulsian's note flags the lower occupancy, the pre IPO brand licensing transaction, and the fact that Temasek, a financial promoter, has held a stake since 2017, terming the overall setup as not particularly healthy for a portfolio. On the more constructive side, Sushil Finance sees meaningful re-rating potential given the scale and brand recall, and a detailed workthrough by IndMoney concludes that valuations look far more reasonable once debt and operating earnings are weighed together rather than looking at the headline PE alone. The grey market premium has stayed thin, around Rs. 9 to 13 a share, or roughly 2 percent over the upper band, suggesting the street itself is not pricing in a big listing pop either way.

Should You Subscribe for the Long Term

Healthcare in India is one of those genuinely structural growth stories, an ageing population, rising insurance penetration and limited quality bed supply relative to demand, themes we have also touched on while discussing why pharma and healthcare are becoming India's new defensive sector. Manipal's scale, brand and metro presence give it a real moat, and the large chunk of licensed but unused bed capacity is arguably more of an upside lever than a red flag, provided management can lift occupancy the way it has in Bengaluru and Kolkata over time.

Set against that is a valuation that leaves very little room for error. Paying close to 85 times trailing earnings for a business whose profit actually declined this year, weighed down by fresh acquisition debt, is not a cheap entry point by any stretch. Investors who already hold Apollo or Max and simply want a third healthcare name in the portfolio get that option here, but there is not much of a cushion if occupancy improvement or the Sahyadri integration takes longer than expected. Those without any hospital sector exposure, comfortable holding through three to five years of execution risk rather than chasing a listing day pop, may find the scale and brand argument worth the price. Either way, treat the size of your application the same way you would size any single stock bet, the thinking in our note on the 3-5-7 rule for money management applies just as much to an IPO allocation as it does to a trading position. And if you would rather let index funds handle stock picking altogether, our comparison of active versus passive investing in India is worth a read before committing fresh capital to a single new listing.

Frequently Asked Questions (FAQ)

1. What is the price band of the Manipal Health IPO?

The price band is fixed at Rs. 560 to Rs. 590 per equity share, with a face value of Rs. 2 each.

2. What is the minimum investment required to apply?

The minimum lot size is 25 shares, which comes to around Rs. 14,750 for retail investors at the upper price band.

3. When will Manipal Health IPO shares get listed?

Allotment is expected on 3 August 2026, and the shares are scheduled to list on both BSE and NSE on 5 August 2026.

4. Is the Manipal Health IPO expensive compared to its peers?

On a trailing price to earnings basis, yes, it is priced around 85 times earnings against a 65 to 75 times range for Apollo, Fortis and Max Healthcare. On an EV to EBITDA basis, however, it looks more reasonably priced against the same peer set.

5. Should long term investors apply for this IPO?

Investors comfortable holding through execution risk from the Sahyadri integration and open to the healthcare growth story may find it worth applying, but the rich valuation leaves little room for error, so position sizing matters.